Critical Research Limitation: Despite extensive preclinical and limited early-phase human studies, the CJC-1295 (NO DAC) + Ipamorelin blend peptide has NO completed, peer-reviewed Phase III clinical trials establishing human safety and efficacy for any medical indication
doi: 10.3389/fimmu.2025.1477437 Received 07 August 2024 Accepted 20 January 2025 Published 10 February 2025 Volume 16 - 2025 Edited by Nejat Dalay, Istanbul University, Trkiye Reviewed by Junwei Luo, Henan Polytechnic University, China Mario Perez-Medina, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico Updates Copyright 2025 Hu, Tian, Liu, Hou, wu, Wang and Shu
Shedrx Review: Clinical Evidence and Personalization Context A Shedrx review reveals important considerations for GLP-1 users: compounded versus branded options, cost transparency, and the role of genetic predispositions in treatment response
Romoser, T.D
Vitamin C and B12 : Vitamin C in high doses can degrade Vitamin B12 in the stomach, reducing its bioavailability
%25201.png)
